LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Home・Elenco Azioni・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

31.16 2.03

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

30.43

Massimo

31.28

Metriche Chiave
By Trading Economics
Entrata	-85K 53M
Vendite	4.2M 153M
P/E Media del settore	17.124 49.8
EPS	0.68
Margine di Profitto	34.53
Dipendenti	182
EBITDA	612K 81M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+10.75% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	577M 3.5B
Apertura precedente	29.13
Chiusura precedente	31.16

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

N/A / 24.28 Supporto e resistenza

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 22:57 UTC

Utili

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mag 2026, 23:52 UTC

Utili

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mag 2026, 23:43 UTC

Utili

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mag 2026, 23:28 UTC

Discorsi di Mercato

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mag 2026, 23:11 UTC

Utili

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mag 2026, 23:06 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mag 2026, 23:05 UTC

Utili

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mag 2026, 23:04 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mag 2026, 23:02 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mag 2026, 22:42 UTC

Utili

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:32 UTC

Utili

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie: 68% of FY Income From International >MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mag 2026, 22:29 UTC

Utili

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mag 2026, 22:26 UTC

Utili

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mag 2026, 22:25 UTC

Utili

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

10.75% in crescita

Previsioni per 12 mesi

Media 33.8 USD 10.75%

Alto 35 USD

Basso 32 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

7 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 7 che hanno fornito valutazioni azionarie a Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.